Nicole Fawcett
Director of Communications, University of Michigan Rogel Cancer

Fawcett leads a team of communicators who produce targeted, innovative communication for the Rogel Cancer Center’s research and clinical enterprises. Prior to Michigan Medicine, Fawcett was a reporter at the Detroit News and editor for a web-based community for people with disabilities.

Nicole Fawcett photo
Cancer protein Stat5 cell yellow
Health Lab
Researchers use a new approach to hit an ‘undruggable’ target
Protein degrader shows promise against STAT5, which plays a role in leukemia and other cancers
microscope cells glioma
Health Lab
Researchers circumvent radiation resistance in subtype of brain tumors
University of Michigan Rogel Cancer Center researchers find ZMYND8 gene plays a critical role in conferring radiation resistance on brain tumors with IDH1 mutation.
Blue green cell microscopic amino
Health Lab
Dietary change starves cancer cells, overcoming treatment resistance
A new study in cells and mice from the University of Michigan Rogel Cancer Center has found that a low-protein diet and a specific reduction in amino acids can improve treatment for colon cancer.
Glioma scientific rendering cancer cells
Health Lab
Unraveling the biology behind aggressive pediatric brain tumor reveals potential new treatment avenue
Precision oncology approach shows potential for high grade gliomas harboring a genetic mutation.
News Release
$7.6 million gift launches new lung cancer research initiative at U-M
Increased understanding of the genetic mutations that drive non-small cell lung cancer has led to new, effective treatments in recent years.
microscopic cell nucleus ribosomes purple
Health Lab
Mathematics enable scientists to understand organization within a cell’s nucleus
A clearer picture of how a cell is organized could help biologists learn how to reprogram a cell to halt cancer or other diseases.
News Release
Daniel Chang to lead department of radiation oncology at Michigan Medicine
The University of Michigan Board of Regents approved the appointment at its Sept. 22 meeting. Chang, who is currently the Sue and Bob McCollum Professor of Radiation Oncology at Stanford University, will begin at U-M on Oct. 1.
Health Lab
New clues to how the tumor microenvironment impacts pancreatic cancer
GOT2 causes metabolic changes that pancreas tumors overcome.
Medicine at Michigan
Arul Chinnaiyan Awarded Prestigious Sjöberg Prize
The prize is awarded by the Royal Swedish Academy of Sciences, which also awards Nobel Prizes
microscopic nanoparticle colorful cellular inhibitor
Health Lab
Outsmarting brain cancer
The approach, studied in mice, overcomes the blood brain barrier and breaks the shield tumors build against the immune response.
Person standing with bag of coins floating, purple background
Health Lab
Crowdfunding helps pay the bills during cancer, but at a price
Crowdfunding to pay medical bills has become increasingly common in the United States. A new study highlights the impact crowdfunding for health care costs has had on young cancer survivors.
News Release
Arul Chinnaiyan awarded prestigious Sjöberg Prize for cancer research
Arul M. Chinnaiyan, M.D., Ph.D., S.P. Hicks Professor of Pathology and Urology at Michigan Medicine, was awarded the 2022 Sjöberg Prize by the Royal Swedish Academy of Sciences, which also awards Nobel Prizes.
Doctors talking in office wearing white lab coats and masks.
Health Lab
Following the science from prostate cancer’s “on switch” to the Sjöberg Prize
Nearly 2 decades after a groundbreaking discovery, Arul Chinnaiyan wins a prestigious cancer research award.
cells under microscope #D render particles
Health Lab
Study demonstrates a novel approach to target enhancer-addicted cancers
A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.
blue xray throat tumor lump with lab note written in blue with yellow overlay on bottom right
Health Lab
Two markers help predict head and neck cancer prognosis
HPV circulating tumor DNA and MRI/PET imaging markers predicted which tumors would respond to chemoradiation as early as two weeks into treatment.
  • 1
  • 2
  • 3